phenylacetic acid and Malignant Melanoma studies

phenylacetic acid and Malignant Melanoma

phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.

Research Excerpts

Excerpt	Relevance	Reference
"By contrast, treatment of melanoma cells that were in a more advanced stage of maturation resulted in profound alterations in cell growth, morphology, and pigmentation consistent with terminal differentiation."	1.29	Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. ( Hudgins, WR; Liu, L; Samid, D; Shack, S; Stetler-Stevenson, WG, 1994)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

2 (66.67)

18.2507

2000's

1 (33.33)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Liu, L	2
Hudgins, WR	2
Miller, AC	1
Chen, LC	1
Samid, D	2
Shack, S	1
Stetler-Stevenson, WG	1
Gervelas, C	1
Avramoglou, T	1
Crépin, M	1
Jozefonvicz, J	1

Studies

Liu, L

Hudgins, WR

Miller, AC

Chen, LC

Samid, D

Shack, S

Stetler-Stevenson, WG

Gervelas, C

Avramoglou, T

Crépin, M

Jozefonvicz, J

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Progressive or Recurrent CNS Malignancy[NCT00006450]	Phase 2	120 participants	Interventional	2000-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Progressive or Recurrent CNS Malignancy[NCT00006450]

Phase 2

120 participants

Interventional

2000-11-30

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for phenylacetic acid and Malignant Melanoma

Article	Year
Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine, 1995, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Cell Differentiation; Culture Media; Gene Expression Regulation, Neoplastic;	1995
Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. The Journal of investigative dermatology, 1994, Volume: 103, Issue:3 Topics: Antineoplastic Agents; Carcinogenicity Tests; Cell Differentiation; Cell Division; Drug Synergism; F	1994
Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate. Anti-cancer drugs, 2002, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dextrans; Dru	2002

Article

Year

Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells.

Cytokine, 1995, Volume: 7, Issue:5

Topics: Antineoplastic Agents; Cell Differentiation; Culture Media; Gene Expression Regulation, Neoplastic;

1995

Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate.

The Journal of investigative dermatology, 1994, Volume: 103, Issue:3

Topics: Antineoplastic Agents; Carcinogenicity Tests; Cell Differentiation; Cell Division; Drug Synergism; F

1994

Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate.

Anti-cancer drugs, 2002, Volume: 13, Issue:1

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dextrans; Dru

2002